Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

BACKGROUND: In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour patients. The study was expanded to focus on patients with metastatic colorectal cancer (CRC). METHODS: Patients received oral regorafenib 60–220 mg daily (160 mg daily in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Strumberg, D, Scheulen, M E, Schultheis, B, Richly, H, Frost, A, Büchert, M, Christensen, O, Jeffers, M, Heinig, R, Boix, O, Mross, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364125/
https://www.ncbi.nlm.nih.gov/pubmed/22568966
http://dx.doi.org/10.1038/bjc.2012.153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364125/
https://www.ncbi.nlm.nih.gov/pubmed/22568966
http://dx.doi.org/10.1038/bjc.2012.153

Ejemplares similares